Cite
HARVARD Citation
Javle, M. et al. (n.d.). P-225Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. Annals of oncology. p. . [Online].